Key Takeaways:
- BioPrime has raised $6 million in Series A funding, led by Belgium-based Edaphon, with participation from Omnivore and Inflexor Ventures.
- The funding will support the development of bio-fungicides, bio-insecticides, and biostimulants in North America, Southeast Asia, and Brazil.
- Trials for biostimulants are underway in the U.S. as BioPrime prepares for international market expansion.
- BioPrime’s BioNexus technology, with access to over 170 microbial strains, aims to accelerate product development.
- Edaphon's first investment in Asia highlights growing interest in sustainable agricultural solutions.
Series A Funding Led by Edaphon
BioPrime has successfully raised $6 million in Series A funding, with Edaphon, a Belgium-based impact fund, leading the round. Existing investors Omnivore and Inflexor Ventures also participated equally in this funding. This investment is Edaphon’s first in Asia, reflecting growing interest in sustainable agricultural innovations.
According to BioPrime's announcement on its LinkedIn page, the funds will be used to advance the company’s work in the field of crop protection, specifically focusing on the development of innovative bio-fungicides and bio-insecticides.
Expanding Biostimulant Range to New Markets
BioPrime also plans to expand its biostimulant range to key markets, including North America, Southeast Asia, and Brazil. The company has already begun trials in the U.S. to support this expansion. The biostimulants aim to improve crop resilience and yield through sustainable practices that reduce the need for traditional chemical inputs.
In a statement shared on its LinkedIn page, BioPrime emphasized its commitment to international growth: “We intend to utilize this financing to extend the biostimulant range to North America, Southeast Asia, and Brazil—trials for these regions are now being conducted in the U.S.”
Leveraging BioNexus Technology
Central to BioPrime’s research and development is its proprietary BioNexus technology. This platform has discovered over 170 unique microbial strains from a library of nearly 18,000 strains, which are being used to accelerate product development for bio-fungicides, bio-insecticides, and biostimulants.
As noted in the company’s LinkedIn post, the BioNexus technology enables BioPrime to expedite the development of biological products that aim to address key challenges in global agriculture.
1 Comment